A Phase 1/2 interventional study of Linvoseltamab and REGN17372+Linvoseltamab in Relapsed Refractory Multiple Myeloma (RRMM), sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 9th largest by planned enrollment, is one of 7 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 14 other live ones, and was the 16th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, France, Japan and 3 more countries
Ages 18+
Multiple Myeloma Research Consortium · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2019; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 168 across the 16 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
15 studies in Multiple Myeloma by Regeneron Pharmaceuticals: 9 open now, 11 under way, 3 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Multiple Myeloma by Regeneron Pharmaceuticals, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 8 of the 10 other live ones, and was the 14th registered.
Regeneron Pharmaceuticals’s Multiple Myeloma studies by the year they started, since 2019.
2 of the studies testing linvoseltamab in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376526Dickran Kazandjian, MDIMMUNOPLANT for Newly Diagnosed Multiple Myeloma | 2027-08-31 |
| NCT07609940Regeneron PharmaceuticalsAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | 2027-10-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, from their registry updates:
Among Regeneron Pharmaceuticals’s 15 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans.
The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone.
The study is looking at:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 Phase 2
Drug: REGN17372+Linvoseltamab
Phase 2
Drug: Linvoseltamab
Administered per protocol
Also known as: Lynozyfic™, REGN5458
Drug page: Linvoseltamab
Administered per the protocol
Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab
Phase 1
Time frame: Up to 35 days
Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab
Phase 1
Time frame: Up to 5 years
Severity of TEAEs associated with REGN17372 in combination with linvoseltamab
Phase 1
Time frame: Up to 5 years
Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs
Phase 2
Time frame: Within 12 weeks of starting cycle 1
VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugs
Phase 2
Time frame: Within 12 weeks of starting cycle 1
PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
Concentrations of REGN17372 in serum
Phase 1 and Phase 2
Time frame: Up to 5 years
Concentrations of linvoseltamab in serum
Phase 1 and Phase 2
Time frame: Up to 5 years
Occurrence of Anti-Drug Antibodies (ADA) to REGN17372
Phase 1 and Phase 2
Time frame: Up to 5 years
Magnitude of ADA to REGN17372
Phase 1 and Phase 2
Time frame: Up to 5 years
Incidence of ADA to linvoseltamab
Phase 1 and Phase 2
Time frame: Up to 5 years
Magnitude of ADA to linvoseltamab
Phase 1 and Phase 2
Time frame: Up to 5 years
Objective Response Rate (ORR) as assessed by IMWG response criteria as determined by the investigator
Phase 1 and Phase 2
Time frame: Up to 5 years
Complete response (CR) as assessed by IMWG response criteria as determined by the investigator
Phase 1 and Phase 2
Time frame: Up to 5 years
VGPR as assessed by IMWG response criteria, as determined by the investigator
Phase 1 and Phase 2
Time frame: Up to 5 years
Duration of Response (DOR) as assessed by IMWG criteria as determined by the investigator
Phase 1 and Phase 2
Time frame: Up to 5 years
Progression Free Survival (PFS) as assessed by IMWG criteria as determined by the investigator
Phase 1 and Phase 2
Time frame: Up to 5 years
Minimal Residual Disease (MRD) negative status (at 10^-5) in participants in CR or better
Phase 1 and Phase 2
Time frame: Up to 5 years
Overall Survival (OS)
Phase 1 and Phase 2
Time frame: Up to 5 years
ORR as assessed using the IMWG response criteria as determined by the investigator in patients receiving combination study drugs
Phase 1
Time frame: Within 12 weeks of starting cycle 1
VGPR assessed using IMWG criteria as determined by the investigator in patients receiving combination study drugs
Phase 1
Time frame: Within 12 weeks of starting cycle 1
Incidence of TEAEs
Phase 2
Time frame: Up to 5 years
Severity of TEAEs
Phase 2
Time frame: Up to 5 years
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Global Health Status / Quality of Life (GHS/QoL)
Phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much"
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-C30 Physical Functioning (PF)
Phase 2
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-C30 Role Functioning (RF)
Phase 2
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-C30 pain
Phase 2
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-C30 fatigue
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 GHS/QoL
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 PF
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 RF
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 pain
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 fatigue
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 GHS/QoL
Phase2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 PF
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 RF
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 pain
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 fatigue
Phase 2
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-Multiple Myeloma Module (MY20) Disease Symptoms (DS)
Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 DS
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 DS
Phase 2
Time frame: Up to 5 years
Change from baseline in EORTC QLQ-MY20 Treatment Side Effects (TSE)
Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 TSE
Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 TSE
Phase 2
Time frame: Up to 5 years
Change from baseline in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS)
Phase 2 The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems
Time frame: Up to 5 years
Time to definitive deterioration in EQ-5D-5L VAS
Phase 2
Time frame: Up to 5 years
Time to first improvement in EQ-5D-5L VAS
Phase 2
Time frame: Up to 5 years
Patient-reported overall impact of treatment toxicity measured by Functional Assessment of Cancer Therapy (FACIT) Item GP5
Phase 2 The FACIT Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much)
Time frame: Up to 5 years
Patient-reported tolerability as measured by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Phase 2 The PRO-CTAE questionnaire assesses side effects and symptoms in cancer clinical trials using a PRO-CTCAE score. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic AEs drawn from the CTCAE
Time frame: Up to 5 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2033, 90 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 90 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab